Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE reported a strong financial performance for the full year 2024, achieving product sales of €163.3 million, reflecting a 13% year-over-year increase compared to €144.6 million in 2023. The company also disclosed total revenue of €169.6 million for 2024, marking a 10% rise from €153.7 million in the prior year, further underpinned by the recent FDA accelerated approval of its Ixchiq vaccine. With expectations of Ixchiq sales surpassing €100 million by the third year post-launch and a projected global market for chikungunya vaccines exceeding $500 million annually, Valneva's growth outlook appears robust, bolstered by its strategic focus on both marketed and developmental vaccine products.
Bears say
Valneva SE is projected to significantly reduce its operating cash burn from over €60.0 million in 2024 to less than €30 million in 2025, indicating a concerted effort to improve financial sustainability. The company's revenue forecast for 2025 has been diminished from €222.5 million to €185 million, which underscores declining sales expectations for its products, particularly Ixchiq. Additionally, the earnings per share (EPS) estimate for 2025 has been adjusted downward from (€0.53) to (€0.65), aligning with the reductions in revenue expectations and highlighting increasing concerns regarding the company’s profitability outlook.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares